These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 38396367)

  • 101. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
    Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
    Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer.
    Fang Y; Wang Y; Zeng D; Zhi S; Shu T; Huang N; Zheng S; Wu J; Liu Y; Huang G; Xue Y; Bin J; Liao Y; Shi M; Liao W
    Oncoimmunology; 2021; 10(1):1951019. PubMed ID: 34345533
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Differences in Immunological Landscape between
    Luo JW; Guo YH; Wu FY; Li XF; Sun XC; Wang JL; Zhou CC
    Dis Markers; 2021; 2021():3776854. PubMed ID: 34484468
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma.
    Li F; Wang S; Wang Y; Lv Z; Jin D; Yi H; Fu L; Zhai S; Xiao T; Mao Y
    Front Immunol; 2023; 14():1101649. PubMed ID: 36845145
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
    Wang S; Xie T; Li Y; Guo L; Ying J; Wang Y; Hao X; Wang X; Li J; Xing P
    Cancer; 2023 Dec; 129(24):3873-3883. PubMed ID: 37538036
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
    Cao H; Ma Z; Huang Q; Han H; Li Y; Zhang Y; Chen H
    Eur J Cancer; 2024 May; 202():113985. PubMed ID: 38452722
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Various impacts of driver mutations on the PD-L1 expression of NSCLC.
    Chu CH; Huang YH; Lee PH; Hsu KH; Chen KC; Su KY; Yu SL; Tseng JS; Yang TY; Chang GC
    PLoS One; 2022; 17(8):e0273207. PubMed ID: 35980949
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
    Jung HA; Park B; Park S; Sun JM; Lee SH; Seok Ahn J; Ahn MJ
    Lung Cancer; 2024 Apr; 190():107536. PubMed ID: 38493759
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Factors correlating the expression of PD-L1.
    Lu F; Wang E; Liu H
    BMC Cancer; 2024 May; 24(1):642. PubMed ID: 38796458
    [TBL] [Abstract][Full Text] [Related]  

  • 111. EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.
    Madeddu C; Donisi C; Liscia N; Lai E; Scartozzi M; Macciò A
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742933
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma.
    Zhao S; Hu X; Zhou P; Li A; Chen L; Wang D; He J; Jiang Y
    Cancer Biol Ther; 2023 Dec; 24(1):2256927. PubMed ID: 38032149
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma.
    Kim H; Lee W; Kim Y; Lee SJ; Choi W; Lee GK; Park SJ; Ju S; Kim SY; Lee C; Han JY
    Exp Mol Med; 2024 Sep; 56(9):2082-2095. PubMed ID: 39300154
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with
    Choudhury NJ; Schoenfeld AJ; Flynn J; Falcon CJ; Rizvi H; Rudin CM; Kris MG; Arcila ME; Heller G; Yu HA; Ladanyi M; Riely GJ
    Clin Cancer Res; 2021 May; 27(10):2920-2927. PubMed ID: 33685865
    [TBL] [Abstract][Full Text] [Related]  

  • 115. The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC.
    Xiong W; Du H; Ding W; Sun J; Xu M; Guo X
    Respir Res; 2020 Jul; 21(1):185. PubMed ID: 32677947
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
    Salas C; Martín-López J; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; Ruiz de Alda L; García JF; Rojo F
    J Clin Pathol; 2022 Mar; 75(3):193-200. PubMed ID: 33722840
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations.
    Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
    Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
    [TBL] [Abstract][Full Text] [Related]  

  • 118. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.
    Raskova Kafkova L; Mierzwicka JM; Chakraborty P; Jakubec P; Fischer O; Skarda J; Maly P; Raska M
    Front Immunol; 2024; 15():1342086. PubMed ID: 38384472
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Multi-index comprehensive evaluation of the efficacy and response mechanism of immunotherapy in non-small cell lung cancer.
    Fan J; Zhang T
    Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38822977
    [TBL] [Abstract][Full Text] [Related]  

  • 120. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
    Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
    Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.